
Immuneering Corp (IMRX) Stock Forecast & Price Target
Immuneering Corp (IMRX) Analyst Ratings
Bulls say
The key points highlighting the positive outlook for Immuneering's stock include the demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) rates compared to current standard-of-care (SoC) treatments, suggesting enhanced efficacy of the company's drug candidates. Additionally, the safety profile of the therapy shows considerable improvement, with favorable tolerability of the drug atebimetinib and a modified regimen leading to better patient outcomes. Furthermore, the advancement of the lead asset, IMM-1-104, along with an extended operational runway through 2029, positions Immuneering to successfully execute its planned Phase III trials, potentially unlocking greater value.
Bears say
The financial outlook for Immuneering Corp faces significant downward pressure primarily due to substantial regulatory risks associated with the approval of its products. Should the company's lead candidate, IMM-1-104, fail to demonstrate distinct benefits in efficacy or tolerability compared to existing profiles, it could lead to revisions in financial estimates and overall valuation. Additionally, the potential need for further capital raises, possibly through equity financing, could dilute existing shareholder value, compounding the company's financial challenges before achieving profitability.
This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares